最新发布

Pacifico Biolabs Closes €7M Series A to Scale Mycelium Protein Through Idle German Brewery Infrastructure

Mycelium fermentation company Pacifico Biolabs has closed a €7 million Series A round to scale production to 200 tonnes per month and begin commercial launches across the DACH region and the Nordics.

Biohub Releases Protein Biology World Model to Address Disease

Biohub,  the non-profit research organization co-founded by Priscilla Chan, MD, and Mark Zuckerberg,  has now unveiled the latest update to the ESM protein language model family, with expanded capabilities in binder design and protein function mapping for therapeutic discovery.   The release comes just seven months after Biohub recruited the team behind EvolutionaryScale.  

Lantmännen First To Adopt Sigill’s New Climate Standards – Certifying This Year’s Harvest

May 2026, Sweden: Lantmännen is the first to adopt Sigill’s new standards for climate measures in crop production and fo…

在马托格罗索州,大豆种植禁令从六月持续到九月。

根据马托格罗索州经济发展秘书处 (Sedec) 和马托格罗索州农业防御研究所 (Indea-MT) 联合发布的新规范性指令,该州 2026/27 作物季的大豆植物检疫日历保持不变。因此,2026 年 6 月 8 日至 9 月 6 日为检疫休整期,2026 年 9 月 7 日至 2027 年 1 月 7 日为大豆种植许可期。

Can plant cell culture escape the biopharma cost trap? Rheaplant nets new funds

Plant cell culture is pricy and difficult. But new food-grade facilities without biopharma cost structures could unlock …

Dairy & Coffee Companies Failing to Set Methane Targets, Finds New Ranking

Danone, General Mills and FrieslandCampina are the only leading dairy and coffee companies in Europe and North America to have publicly set targets to reduce methane emissions, according to a new ranking by Changing Markets Foundation.

大田种植″高效桶混″时代,西班牙Bioiberica新一代生物刺激素如何兼顾营养、抗逆与″安全剂″功效?

世界农化网中文网报道: 在大田作物种植体系中,作业窗口期短且为单通道,多产品桶混是常规操作模式。西班牙比欧伊贝利卡生化制品公司(Bioiberica)的生物刺激素Terra-Sorb® granum专为桶混应用而设计,同时提供有助于初级代谢(尤其是氮-硫同化过程)的成分,并添加精选微量元素和L-α-氨基酸。除了营养贡献外,L-α-氨基酸还可视为功能性成分,有利于提升复杂桶混喷液的性能。

Are we ready for the next wave of proximity degraders? 

You may have heard of molecular glue degraders; dubbed nature’s matchmakers, these are small molecules that help ‘glue’ proteins to each other, one being a rogue protein previously regarded as undruggable. Traditional proximity medicines are aimed at drugging these undruggable targets, but new proximity medicines are on the way to make this process more efficient as novel ways to discover targets are explored.  

Hansa data supports full approval plan for Idefirix

The open-label confirmatory study evaluated Idefirix (imlifidase) in highly sensitised patients undergoing HLA-incompatible kidney transplantation. These patients carry donor-specific antibodies that can trigger rejection and make it difficult, or sometimes impossible, to find a compatible donor kidney. Imlifidase is used before transplantation to cleave IgG antibodies and convert a positive crossmatch against a deceased donor to negative.

Ex-Palantir execs raise $12M to develop AI operating system at Perceptic

Tilman Flock, Martin Copes and Zaki Trache cofounded Perceptic, which has a presence in London and Basel, after working together at Palantir. The trio collaborated on Palantir’s AI platform and life sciences activities, giving them experience of securely connecting artificial intelligence models to organizations’ internal data and operations. Flock, Copes and Trache are applying that experience to Perceptic.